Articles published by Athersys, Inc.
 
   From Athersys, Inc.
   Via Business Wire
    
    
    
    
   
    Athersys Licenses its Animal Health Assets to Ardent Animal Health
    
   October 03, 2023
   From Athersys, Inc.
   Via Business Wire
    Tickers
      ATHX
    
    
   
    Athersys Director Jane Wasman Appointed Board Chair
    
   October 02, 2023
   From Athersys, Inc.
   Via Business Wire
    Tickers
      ATHX
    
    
   
    Grant Awarded to Newcastle University to Research Athersys’ MultiStem® in Machine Perfusion Prior to Kidney Transplantation
    
   September 06, 2023
   From Athersys, Inc.
   Via Business Wire
    Tickers
      ATHX
    
    
   
    Athersys, Inc. Announces Pricing of $3.5 Million Public Offering
    
   August 17, 2023
   From Athersys, Inc.
   Via Business Wire
    Tickers
      ATHX
    
    
   From Athersys, Inc.
   Via Business Wire
    Tickers
      ATHX
    
    
   
    Athersys Appoints Neema Mayhugh, PhD to its Board of Directors
    
   August 11, 2023
   From Athersys, Inc.
   Via Business Wire
    Tickers
      ATHX
    
    
   From Athersys, Inc.
   Via Business Wire
    Tickers
      ATHX
    
    
    
   
    Athersys Restructures Debt with Supplier
    
   May 23, 2023
   From Athersys, Inc.
   Via Business Wire
    Tickers
      ATHX
    
    
   From Athersys, Inc.
   Via Business Wire
    Tickers
      ATHX
    
    
   From Athersys, Inc.
   Via Business Wire
    Tickers
      ATHX
    
    
    
   
    Athersys to Participate in The American Society for Neural Therapy and Repair Annual Conference
    
   April 21, 2023
   From Athersys, Inc.
   Via Business Wire
    Tickers
      ATHX
    
    
   
    Athersys, Inc. Announces Closing of $3.7 Million Registered Direct Offering and Concurrent Private Placement
    
   April 19, 2023
   From Athersys, Inc.
   Via Business Wire
    Tickers
      ATHX
    
    
   
    Athersys, Inc. Announces $3.7 Million Registered Direct Offering and Concurrent Private Placement
    
   April 18, 2023
   From Athersys, Inc.
   Via Business Wire
    Tickers
      ATHX
    
    
   From Athersys, Inc.
   Via Business Wire
    Tickers
      ATHX
    
    
   
    Athersys Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
    
   March 31, 2023
   From Athersys, Inc.
   Via Business Wire
    Tickers
      ATHX
    
    
   
    Athersys Announces Successful Type B Meeting with the FDA
    
   March 22, 2023
   From Athersys, Inc.
   Via Business Wire
    Tickers
      ATHX
    
    
   From Athersys, Inc.
   Via Business Wire
    Tickers
      ATHX
    
    
   
    Athersys Granted Clinical Type B Meeting with FDA for MASTERS-2 Clinical Trial Protocol Discussion
    
   February 14, 2023
   From Athersys, Inc.
   Via Business Wire
    Tickers
      ATHX
    
    
   
    Athersys to Host Business Update Conference Call on February 14th
    
   February 02, 2023
   From Athersys, Inc.
   Via Business Wire
    Tickers
      ATHX
    
    
   
    Athersys to Participate in International Stroke Conference and BioProcess International
    
   January 30, 2023
   From Athersys, Inc.
   Via Business Wire
    Tickers
      ATHX
    
    
   
    Athersys to Participate in Advanced Therapies Week and Allogeneic Cell Therapies Summit Europe in January
    
   January 11, 2023
   From Athersys, Inc.
   Via Business Wire
    Tickers
      ATHX
    
    
   
    Athersys Provides MultiStem Clinical Update
    
   January 09, 2023
   From Athersys, Inc.
   Via Business Wire
    Tickers
      ATHX
    
    
   
    Athersys Appoints Joseph Nolan to Its Board of Directors
    
   January 05, 2023
   From Athersys, Inc.
   Via Business Wire
    Tickers
      ATHX
    
    
   
    Athersys Reports Third Quarter 2022 Financial Results and Provides Business Update
    
   November 15, 2022
   From Athersys, Inc.
   Via Business Wire
    Tickers
      ATHX
    
   
   Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
  
  
 Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
  © 2025 FinancialContent. All rights reserved.
 
